BioPharmSignal logoBioPharmSignal

Biotech News

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Aquestive Therapeutics (AQST)Aquestive Therapeutics2026-06-25 13:46 ESTFDA / regulatory

Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026; Type A meeting with FDA expected to occur within 30 days On track to submit regulatory applications for Anaphylm in Canada and the EU in 2026 Extends revenue sharing agreement with RTW to June 30, 2027

Open original release

Related news

AQSTAquestive Therapeutics2026-06-25 13:46 EST

Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

AQSTAquestive Therapeutics2026-06-25 13:46 EST

Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree

AQSTAquestive Therapeutics2026-06-25 13:46 EST

Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer

AQSTAquestive Therapeutics2026-06-25 13:46 EST

Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting

AQSTAquestive Therapeutics2026-06-25 13:46 EST

Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

AQSTAquestive Therapeutics2026-06-25 13:46 EST

Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET

AQSTAquestive Therapeutics2026-06-25 13:46 EST

Aquestive Therapeutics to Participate in Upcoming March Investor Conferences

AQSTAquestive Therapeutics2026-06-25 13:46 EST

Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)

AQSTAquestive Therapeutics2026-06-25 13:46 EST

Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer

AQSTAquestive Therapeutics2026-06-25 13:46 EST

Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

View all latest news

Aquestive Therapeutics

Aquestive Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

AQSTAquestive Therapeutics2026-06-26 10:42 EST

Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

AQSTAquestive Therapeutics2026-06-26 10:42 EST

Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree

AQSTAquestive Therapeutics2026-06-26 10:42 EST

Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer

AQSTAquestive Therapeutics2026-06-26 10:42 EST

Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting

AQSTAquestive Therapeutics2026-06-26 10:42 EST

Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States